What is LXRX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.64B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LXRX?

P/E (TTM) is n/a and 52-week range is $1.10 to $2.68 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LXRX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LXRX?

The company profile lists revenue (TTM) near $42M, net income (TTM) near -$6.22B, EPS (TTM) near -$0.15 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Lexicon Pharmaceuticals, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in The Woodlands, Texas, US, 445M shares outstanding, ISIN US5288723027 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Lexicon Pharmaceuticals, Inc.

$LXRX

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 81 full-time employees. The company went IPO on 2000-04-07. The firm is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The firm develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The firm also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.

Employees

Website

www.lexpharma.com/

IPO

2000-04-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US5288723027

Headquarters

The Woodlands, Texas, US

Shares outstanding

445M

NAICS sector

Manufacturing

Institutional ownership

83.72%

Browse other companiesFree AI scores and summaries for more stocks